Promising combo trial for brain metastases halted after just 3 patients
NCT ID NCT05746481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tested two immune-boosting drugs, tiragolumab and atezolizumab, with or without chemotherapy, in people with non-small cell lung cancer that had spread to the brain. The goal was to see if the combination could control the brain tumors and delay the need for radiation. However, the study was terminated early after enrolling only 3 participants, so no meaningful conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tiragolumab and atezolizumab (immune-boosting drugs)
What this could lead to
If it worked, this combination might help control lung cancer that has spread to the brain without needing radiation.
What could go wrong
The trial was terminated early with only 3 participants, so we have very little data. It is unclear if the drugs are safe or effective for this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States